ARTICLE | Product Development
Sage broadens the spotlight on postpartum depression
Sage is using Zulresso’s launch to raise awareness of postpartum depression
March 30, 2019 1:01 AM UTC
Sage is parlaying the launch of the first drug for postpartum depression into improved awareness and diagnosis, setting up its next therapy to launch into a larger, better prepared market.
On March 19, FDA approved Zulresso brexanolone, a positive-allosteric modulator of the GABA A receptor, on the back of Phase III results showing the compound reduced depressive symptoms within 60 hours, a much speedier time-course than the weeks to months it takes other marketed antidepressants to take effect. ...
BCIQ Company Profiles